Corvus Pharmaceuticals Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Corvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% Following Weak Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price fell 6.5% during trading on Friday following a dissappointing earnings announcement. The stock traded as low as $15.12 and last traded at $14.9750. 286,811 shares were traded during trading, a decline of 93% from the average session volume of 3,917,681 shares. The stock had previously
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark.
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know
Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon
Corvus Pharmaceuticals, Inc. reported highly positive phase 1 cohort 4 data for soquelitinib in moderate-to-severe atopic dermatitis. 75% of patients on 200 mg soquelitinib BID achieved EASI 75, with benefits persisting one month post-treatment. Longer treatment duration improved outcomes, including for patients previously treated with other therapies.
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know
Corvus Pharmaceuticals, Inc. stock surged 165% on strong Phase 1 soquelitinib data in moderate-to-severe atopic dermatitis, including treatment-resistant patients. Soquelitinib achieved 75% EASI-75 and 33% IGA 0/1 rates, with favorable safety and biomarker evidence supporting its differentiated immunomodulatory mechanism. CRVS initiated a $150M equity offering to extend cash runway and fund pivotal Phase 2/3 trials, with durability of response as the next critical catalyst.
